>
Pharmaxis logo

PXS - Pharmaxis Share Price

A$0.081 0.0  0.0%

Last Trade - 6:10am

Sector
Healthcare
Size
Micro Cap
Market Cap £17.7m
Enterprise Value £11.6m
Revenue £12.2m
Position in Universe 1299th / 1911
Bullish
Bearish
Unlock PXS Revenue
Momentum
Relative Strength (%)
1m +2.84%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -52.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
58.6 18.6 17.6 50.3 12.5 12.6 23.1 17.6 -26.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, PharmaxisLtd. revenues increased from A$3.7M to A$13.4M. Net incometotaled A$46K vs. loss of A$10.3M. Revenues reflectMannitol segment increase from A$3.3M to A$13.2M. NetIncome reflects Foreign currency exchange gains & lossesincrease from A$121K (expense) to A$1.4M (income), Drugdevelopment decrease of 30% to A$917K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PXS Revenue Unlock PXS Revenue

Net Income

PXS Net Income Unlock PXS Revenue

Normalised EPS

PXS Normalised EPS Unlock PXS Revenue

PE Ratio Range

PXS PE Ratio Range Unlock PXS Revenue

Dividend Yield Range

PXS Dividend Yield Range Unlock PXS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PXS EPS Forecasts Unlock PXS Revenue
Profile Summary

Pharmaxis Ltd is a research pharmaceutical company with a portfolio of products at various stages of development and approval. The Company is engaged in research, development and commercialization of human healthcare products for the treatment and management of chronic diseases. Its segments include Bronchitol and Aridol, which covers the ongoing clinical development, manufacture and sale of the Bronchitol and Aridol across the globe; New Drug Development, which encompasses the drug discovery and early-stage clinical development of its new drug candidates, and Corporate. The Company's development pipeline is focused on amine oxidase chemistry and includes Semicarbazide‐Sensitive Amine Oxidase Inhibitors (SSAO) for Non‐alcoholic Steatohepatitis (NASH) and inflammatory diseases, including kidney fibrosis and chronic obstructive pulmonary disease (COPD), and lysyl oxidase inhibitors (LOX) targeting fibrotic diseases, including NASH, pulmonary fibrosis and some cancers.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated May 29, 1998
Public Since November 10, 2003
No. of Shareholders: 4,670
No. of Employees: 107
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 397,179,798
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PXS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PXS
Upcoming Events for PXS
Friday 30th July, 2021
Q2 2021 Pharmaxis Ltd Cashflow Reports
Friday 13th August, 2021
Full Year 2021 Pharmaxis Ltd Earnings Release
Friday 29th October, 2021
Q3 2021 Pharmaxis Ltd Cashflow Reports
Frequently Asked Questions for Pharmaxis
What is the Pharmaxis share price?

As of 6:10am, shares in Pharmaxis are trading at A$0.081, giving the company a market capitalisation of £17.7m. This share price information is delayed by 15 minutes.

How has the Pharmaxis share price performed this year?

Shares in Pharmaxis are currently trading at A$0.081 and the price has moved by -6.9% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pharmaxis price has moved by -28.79% over the past year.

What are the analyst and broker recommendations for Pharmaxis?

Of the analysts with advisory recommendations for Pharmaxis, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pharmaxis is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Pharmaxis next release its financial results?

Pharmaxis is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Pharmaxis dividend yield?

Pharmaxis does not currently pay a dividend.

Does Pharmaxis pay a dividend?

Pharmaxis does not currently pay a dividend.

When does Pharmaxis next pay dividends?

Pharmaxis does not currently pay a dividend.

How do I buy Pharmaxis shares?

To buy shares in Pharmaxis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pharmaxis?

Shares in Pharmaxis are currently trading at A$0.081, giving the company a market capitalisation of £17.7m.

Where are Pharmaxis shares listed? Where are Pharmaxis shares listed?

Here are the trading details for Pharmaxis:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PXS
What kind of share is Pharmaxis?

Based on an overall assessment of its quality, value and momentum, Pharmaxis is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pharmaxis share price forecast 2021?

Shares in Pharmaxis are currently priced at A$0.081. At that level they are trading at 72.84% discount to the analyst consensus target price of 0.00.

Analysts covering Pharmaxis currently have a consensus Earnings Per Share (EPS) forecast of -0.014 for the next financial year.

How can I tell whether the Pharmaxis share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmaxis. Over the past six months, the relative strength of its shares against the market has been -21.73%. At the current price of A$0.081, shares in Pharmaxis are trading at -9.43% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pharmaxis PE Ratio?

We were not able to find PE ratio data for Pharmaxis.

Who are the key directors of Pharmaxis?

Pharmaxis's management team is headed by:

David McGarvey - CFO
Brett Charlton - OTH
Gary Phillips - CEO
Malcolm McComas - NEC
William Delaat - NID
Wolfgang Jarolimek - OTH
Kristen Morgan - OTH
Kathleen Metters - NID
Neil Graham - NED
Who are the major shareholders of Pharmaxis?

Here are the top five shareholders of Pharmaxis based on the size of their shareholding:

BVF Partners L.P. Hedge Fund
Percentage owned: 17.09% (77.3m shares)
Karst Peak Capital Limited Hedge Fund
Percentage owned: 8.89% (40.2m shares)
Moggs Creek Proprietary Ltd. Corporation
Percentage owned: 1.57% (7.10m shares)
Cohen (Toby David) Individual Investor
Percentage owned: 0.89% (4.02m shares)
Phillips (Gary Jonathan) Individual Investor
Percentage owned: 0.51% (2.33m shares)
Similar to PXS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.